Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 81, Issue 1, Pages 17-38Publisher
SPRINGER
DOI: 10.1007/s00280-017-3501-8
Keywords
Ovarian cancer; Biological drugs; Targeted therapy; Clinical trials
Categories
Funding
- Narodowe Centrum Nauki [UMO-2012/04/M/NZ2/00133]
Ask authors/readers for more resources
Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available